To animate the Banner

Picture Name

Apply for post


Recruitment Position

Place of work

Number of Recruits

Salary Treatment

Obutiinib 3

Obitinib (trade name: Yinokai) is a highly selective new BTK inhibitor independently developed by Nuo Cheng Jianhua. Obitinib has an innovative compound structure, resulting in high selectivity, reduced off-target effects, and better efficacy and safety. Phase III clinical trials of orbutib for first-line treatment of mantle cell lymphoma (MCL) are ongoing worldwide. MCL is a subtype of B- cell non-Hodgkin lymphoma caused by malignant transformation of B lymphocytes in the follicular mantle region of the lymph node. MCL is most common in men with a median age of 60 years, and most patients are at an advanced stage of disease at the time of diagnosis.

Gender
Marriage
kg
cm
Please upload a resume file smaller than 5M ~